Pozen's shares soar as FDA approves study results

Chapel Hill, NC-based Pozen saw its stock soar Thursday on the news that the FDA accepted its primary endpoint for two late-stage clinical trials PN 400, its arthritis drug. PN 400, which is being developed in partnership with AstraZeneca, combines the painkiller naproxen with AstraZeneca's Nexium (esomeprazole). Results from the trials showed that the investigational drug reduced the number of gastric ulcers, thus meeting the primary endpoint.

Back in October, the FDA informed the company that the agency would conduct a review of the acceptability of gastric ulcer incidence as a primary endpoint, raising concerns that Pozen would have to devote more time and resources to conduct further trials. Now that the company can move forward, Pozen says it plans to submit a new drug application to the FDA by mid-2009.

Investors were clearly excited about the news. According to Forbes, shares of Pozen rose 22 percent to $7.44 in midday trading.

- read the Pozen release
- read the AP article in Forbes article for more

Suggested Articles

Imbruvica has enjoyed a nice run in previously untreated CLL over the last few years. But major competition is here in the form of AZ's Calquence.

Pennsylvania's Supreme Court revived thousands of lawsuits alleging the antipsychotic med Risperdal caused males to develop breasts.

In the asthma biologics race, there doesn't appear to be a clear favorite among Xolair, Dupixent, Fasenra and Nucala for a group of pulmonologists.